Lantheus Announces the Approval of DEFINITY by China’s NMPA
28 Nov 2022 //
PRESS RELEASE
FDA Approves GE Healthcare for Contraindications in PI for Optison
05 Oct 2021 //
BUSINESSWIRE
Health Canada Issues Class II Drug Recall of Alburex-25 Solution
11 Feb 2019 //
HEALTH CANADA